[drug gajun] among the approved new drugs in 2017, these 12 drugs have unlimited potential. CDE undertook the listing application of Junshi biological and Hengrui class 1 new drugs, and FDA approved another new drug to be listed

In 2017, 12 new drugs were approved by FDA with unlimited potential In 2017, 47 new drugs were approved by FDA Recently, clarivate analytics, an American company, analyzed and predicted them It is estimated that 12 of the 47 new drugs will have sales of more than 1 billion US dollars by 2020 (as shown in the figure below) It is worth noting that only one of them is a cancer drug, two drugs for diabetes and nine drugs for other diseases In addition to some brand enterprises, there are also some emerging pharmaceutical companies, such as Alnylam and GW pharmaceuticals and individual companies One week news of medicine this week, three new drug clinical applications and two new drug marketing applications were undertaken in China, new GSK COPD drug olexin was launched, new Novartis asthma drug omazumab was officially used in clinical practice, and new psoriasis drug ilumya was launched in the world Gamma (tildrakizumab aSMn) has been approved by the FDA for marketing, latuda (lurasidone), a new bipolar disorder drug, has been approved to treat children, xtandi (enzalutamide), a new Pfizer prostate cancer drug, has obtained the priority evaluation qualification.. Details are shown in the following figure: content source: intelligence data, medical information center, economic observation network, Wuxi apptec, etc